Frequently Requested
ORA Documents and FDA 483s
Last Update: August 3, 2004
Frequently requested ORA documents disclosed pursuant to the Freedom of Information Act
(FOIA): (Redacted per 21 CFR Part 20):
- American
National Red Cross/Biomedical Services, Washington, D.C., July 13, 2004 Letter [HTML], PDF
size 29 KB
- American National Red Cross/Biomedical Services, Washington, D.C.,
April 2, 2004, Adverse Determination Letter[HTML], PDF
size 33 KB
- American National Red Cross/Biomedical Services, Washington, D.C.,
March 8, 2004, Consent Decree Correspondence [HTML], PDF
size 20 KB
- American National Red Cross/Biomedical Services, Washington, D.C.,
February 11, 2004, Adverse Determination Letter [HTML],
PDF size 191 KB
- CryoLife, Inc., Kennesaw, GA, FDA Inspectional Observations, dated
10/9, 10, & 14/2003 [PDF]
size 31 KB [HTML]
- American National Red Cross/Biomedical Services, Washington, D.C.,
September 2, 2003, Consent Decree Correspondence [HTML], PDF
size 660 KB
- American National Red Cross/Biomedical Services, Washington, D.C.,
July 22, 2003, Adverse Determination Letter [HTML],
PDF size 5.6 MB
- American National Red Cross/Biomedical Services, Washington, D.C.,
April 15, 2003, Amended Consent Decree [HTML], Part1
PDF size 3.6 MB Part2 PDF size
12.8 MB
- American National Red Cross/Biomedical Services, Arlington, Virginia,
April 14, 2003, Consent Decree Letter [HTML],
PDF
size 327 KB
- Cryolife, Connie J. Jones, Kennesaw, GA, 30144, FDA Inspectional
Observations, dated 2/14/2003, PDF
size 3198 KB, [HTML]
- University of Illinois @ Urbana - Champaign (Sponsor), Champaign,
Illinois, 01/29, 30 & 31/2003, FDA Inspectional Observations
PDF
size 30 KB, [HTML]
- American National Red Cross/Biomedical Services, Arlington, Virginia
, 04/22/2002 to 12/20/2002 FDA Inspectional Observations PDF
size 1845 KB, [HTML]
- CryoLife, Inc., Kennesaw, GA, August 13, 2002 Order for Retention,
Recall, and/or Destruction [PDF] size 279KB [HTML]
- Gary J. Oulette, Executive Director, American Red Cross, Greater
Chesapeake & Potomac Blood Service Region, FDA 483, Insp. Observations
(Baltimore) 06/21/2002 posted 07/15/2002
HTML
- Chi Van Dang, M.D., Ph.D./John Hopkins School of Medicine, IRB
FDA 483, Insp. Observations (Baltimore) 09/07/2001
[PDF]
size 4.62 MB
[HTML]
- Chi Van Dang, M.D., Ph.D./John Hopkins, Bayview Medical Center,
Human Subjects Committee
FDA 483, Insp. Observations (Baltimore) 09/07/2001
[PDF] size 2.59 MB
[HTML]
- Alkis Togias, M.D./Johns Hopkins Asthma & Allergy Clinic,
Baltimore, MD.:
FDA 483, Inspectional
Observations; (Baltimore) 06/28/2001 [HTML]
- Schering-Plough, Manati, Puerto Rico:
FDA 483, Insp.Observations:
(Manati) 06/13/2001, 6.0 MB PDF
FDA 483, Insp.Observations:
(Las Piedras) 06/05/2001, 1.4 MB PDF
FDA 483, Insp.Observations;
(Manati) 02/16/2001, 1.0 MB PDF
FDA 483, Insp.Observations;
(Las Piedras) 02/16/2001, 2.3 MB PDF
FDA 483, Insp.Observations;
(Manati) 12/14/2000, 1.1 MB PDF
FDA 483, Insp.Observations;
(Manati)(03/28/2000), 1.3 MB PDF
- Eli Lilly and Company, Indianapolis, IN. Inspection January
29 to February 23, 2001, Warning Letter, FDA 483 and responses
from firm:
FDA
483, dated 02/23/2001; 4.26 MB PDF;
Warning
Letter, dated 03/02/2001; 384 KB PDF
Response
(interim) dated 03/08/2001; 227 KB PDF
Response
to FDA dated 03/08/2001; 9.2 MB PDF
- Bioport Corporation, Lansing, MI
FDA 483,
dated 10/10-26/2000, (18 pages) 3.3MB PDF
- New York Blood Center, Inc., New York, NY
Establishment Inspection Report (EIR) (inspection
10/29/1996 to 12/20/1996) 5MB PDF
- Time Cap Labs, Inc., Farmingdale, NY
FDA 483, (inspection
03/26 - 05/05/1998) 1.6 MB PDF
- Forest/Inwood Laboratories, Inc., Farmingdale, NY
FDA 483,
dated 10/23/1998, 394KB PDF
- FDA Freedom of Information Reading
Room and
Warning Letters
|